Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Breast Neoplasms 4Neoplasm Metastasis 3Thyroid Neoplasms 1Prostate Carcinoma Metastatic to the Bone 1Prostate Cancer Metastatic to Bone 1Prostate Adenocarcinoma 1Lung Neoplasms 1Hormone Refractory Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Docetaxel 3sargramostim 1radium Ra 223 dichloride 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1Prednisone 1Mycobacterium w vaccine 1Everolimus 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone Refractory Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Bayer

Phase 2 Completed
100 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡